Bullish flow in UiPath (PATH), with shares up 62c, or 3.88%, near $16.75. Options volume roughly in line with average with 54k contracts traded and calls leading puts for a put/call ratio of 0.11, ...

Palantir has been one of the best growth stories in the market. UiPath is just beginning to see its revenue growth accelerate as it looks to become an AI agent orchestration platform. UIPath's ...

AI Cloud 3.1 adds Nvidia Blackwell plus governance tools; catalysts include adoption and Feb 18 earnings. Read more analysis ...

UiPath (PATH) just checked several key boxes for investors at once, moving from GAAP losses to profit while accelerating revenue growth and doubling down on its agentic AI and automation platform ...

Excellence in business comes in many forms. For some companies, it’s a creative use of artificial intelligence to drive growth. For others, it’s a viral marketing campaign or a game-changing invention ...

Dec 11 (Reuters) - The U.S. Food and Drug Administration has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to typical antidepressants that ...

UiPath Inc. (PATH) is one of a bunch of software companies that went public in 2021, saw its shares subsequently collapse, and have seemingly never managed to make a recovery. And to be fair, many of ...

As a writer for Forbes Home since 2021, Emily specializes in writing about home warranties, solar installations, car transportation and moving companies. With a background in journalism and experience ...

The FDA has approved its first at-home, nondrug therapy for depression, with a wearable brain stimulation headset developed by Flow Neuroscience. The agency issued a green light that covers the device ...